Lista de obras - Kieran F Docherty - Dominio Público Uruguay

Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction

artículo científico publicado en 2018

Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?

scientific article published on 16 January 2019

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

artículo científico publicado en 2020

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

artículo científico publicado en 2019

Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?

artículo científico publicado en 2018

Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

scientific article published on 04 September 2020

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

artículo científico publicado en 2020

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

artículo científico publicado en 2020

Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT

scientific article published on 09 May 2016

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

artículo científico publicado en 2019

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

artículo científico publicado en 2020

Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF

scientific article published on 23 December 2020

How robust are clinical trials in heart failure?

artículo científico publicado en 2016

Prevalence and incidence of intraventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE

artículo científico publicado en 2020

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

artículo científico publicado en 2019

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.

artículo científico publicado en 2019

Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?

artículo científico publicado en 2012

Lista de obras de Kieran F Docherty

Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction

Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?

Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF

How robust are clinical trials in heart failure?

Prevalence and incidence of intraventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.

Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?